For Immediate Release
Chicago, IL – March 24, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers Squibb BMY, BHP Group BHP, CVS Health CVS, T-Mobile US TMUS and Anthem ANTM.
Here are highlights from Monday’s Analyst Blog:
Stock Market Research for Bristol Myers, BHP and CVS Health
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb, BHP Group and CVS Health. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Bristol-Myers’ shares have outperformed the Zacks Large Cap Pharmaceuticals over the past six months (-3.2% vs. -11.9%). The Zacks analyst believes that Bristol-Myers’ blockbuster immuno-oncology drug, Opdivo, and Eliquis have maintained the company’s momentum. Label expansion of Opdivo into additional indications should further boost the top line.
Empliciti and Sprycel are also performing well on label expansions. Blood thinner drug, Eliquis, is expected to drive further growth, propelled by increased share in the NOAC market. Meanwhile, the acquisition of Celgene has strengthened the company’s oncology portfolio with the addition Revlimid.
The acquisition will also strengthen the company’s pipeline with encouraging candidates. However, concerns will rise once Revlimid loses patent protection. Moreover, the company is facing headwinds like stiff competition from other immuno-oncology drugs and pipeline setbacks.
Shares of BHP have lost 40.3% over the past year against the Zacks Mining - Miscellaneous industry’s fall of 38.7%. The Zacks analyst believes that BHP Group’s strong cash flow and focus on lowering debt are likely to enhance its capability.
The company maintains capital and exploration expenditure guidance below $8 billion for fiscal 2020 and $8 billion for fiscal 2021. It currently has six major projects under development in petroleum, copper, iron ore and potash. Efforts to make operations more efficient on the back of smarter technology adoption across the entire value chain will drive growth.
However, slowdown in global growth and lower commodity prices due to the coronavirus outbreak is likely to impact results. The consensus estimate for earnings for the current fiscal has undergone negative revision lately. Nevertheless, even though metal prices remain subdued in the near term, it will eventually pick up on the back of the impending demand-supply imbalance.
CVS Health’s shares have lost 26.6% over the past three months against the Zacks Retail Pharmacies and Drug Stores industry’s fall of 25.1%. The Zacks analyst believes that the company’s recently-introduced Health Care Benefits segment, following the Aetna acquisition, holds immense promise.
Additionally, solid year-over-year Retail/LTC comparisons were impressive. Strong expansion of both margins further buoys optimism on the stock. The expansions of MinuteClinics and HealthHUBs during the quarter are also encouraging. CVS Health ended the fourth quarter with better-than-expected numbers. However, the LTC business is facing some industry-wide challenges. Reimbursement risk continues to be a dampener.
Other noteworthy reports we are featuring today include T-Mobile US and Anthem.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BHP Group Limited (BHP): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Anthem, Inc. (ANTM): Free Stock Analysis Report
T-Mobile US, Inc. (TMUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.